相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Implications of the tumor immune microenvironment for staging and therapeutics
Janis M. Taube et al.
MODERN PATHOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Breast Cancer Immunotherapy: Facts and Hopes
Leisha A. Emens
CLINICAL CANCER RESEARCH (2018)
Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication
Samantha Burugu et al.
BREAST CANCER (2017)
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma
Axel Lechner et al.
ONCOTARGET (2017)
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma Implications for Immunotherapy
Elizabeth L. Yanik et al.
JAMA ONCOLOGY (2017)
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis
Hye Min Kim et al.
BMC CANCER (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
New Strategies in Breast Cancer: Immunotherapy
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
Ashley Cimino-Mathews et al.
HUMAN PATHOLOGY (2016)
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Rita Nanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
The immune microenvironment of breast ductal carcinoma in situ
Elizabeth Thompson et al.
MODERN PATHOLOGY (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Nicolas A. Giraldo et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients
Hojabr Kakavand et al.
CLINICAL CANCER RESEARCH (2015)
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Louisa Mezache et al.
MODERN PATHOLOGY (2015)
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
Jaemoon Koh et al.
MODERN PATHOLOGY (2015)
Tumor PD-L1 expression, immune cell correlates and PD-1+lymphocytes in sentinel lymph node melanoma metastases
Hojabr Kakavand et al.
MODERN PATHOLOGY (2015)
Releasing the Brakes on Cancer Immunotherapy
Antoni Ribas
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade
Philipp Mueller et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A. D'Incecco et al.
BRITISH JOURNAL OF CANCER (2015)
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
Nicolas J. Llosa et al.
CANCER DISCOVERY (2015)
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer
Hallie Wimberly et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
Zoran Gatalica et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Ductal Carcinoma In Situ of the Breast
Kalliopi P. Siziopikou
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2013)
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
S. Muenst et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
Patrick A. Ott et al.
CLINICAL CANCER RESEARCH (2013)
Immunotherapeutics for breast cancer
Carmen Criscitiello et al.
CURRENT OPINION IN ONCOLOGY (2013)
Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Hee Jin Lee et al.
JOURNAL OF BREAST CANCER (2013)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
Identification of a basal-like subtype of breast ductal carcinoma in situ
Chad A. Livasy et al.
HUMAN PATHOLOGY (2007)
Inflammation and breast cancer - Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression
David G. DeNardo et al.
BREAST CANCER RESEARCH (2007)
Ductal carcinoma in situ with basal-like phenotype:: a possible precursor to invasive basal-like breast cancer
BB Bryan et al.
MODERN PATHOLOGY (2006)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
分享论文
